The recent deal with CVS Health Corp. and Aetna Inc. has attracted scrutiny for antitrust issues. Although the deal has implied to improve the accessibility and efficiency of healthcare for consumers, past settlements with behavioral restrictions have received tough criticism.
"That doesn’t mean there’s heightened hostility toward vertical deals at the Justice Department, but CVS might prefer the Aetna deal to go to the FTC given Delrahim’s criticism of behavioral fixes," said Attorney David Kully.
Please note that email communications to the firm through this website do not create an attorney-client relationship between you and the firm. Do not send any privileged or confidential information to the firm through this website. Click "accept" below to confirm that you have read and understand this notice.